Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 3/20 | 0.46 |
| ▸ | CNR2 | P34972 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.45 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.45 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.45 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.45 |
| ▸ | TLR2 | O60603 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8004697 | 0.85 | PLA2G2A (0.51) | CNR1CNR2ALDH1A1PLA2G2APLA2G10 | |
| SCHEMBL8004701 | 0.85 | PLA2G2A (0.51) | CNR1CNR2ALDH1A1PLA2G2APLA2G10 | |
| SCHEMBL8356097 | 0.84 | CNR2 (0.56) | CNR1CNR2ALDH1A1PLA2G2APLA2G10 | |
| SCHEMBL3490890 | 0.82 | PLA2G2A (0.49) | CNR1CNR2ALDH1A1PLA2G2APLA2G10 | |
| SCHEMBL3490896 | 0.82 | PLA2G2A (0.49) | CNR1CNR2ALDH1A1PLA2G2APLA2G10 | |
| SCHEMBL8357825 | 0.81 | PLA2G2A (0.59) | PLA2G2APLA2G10PLA2G1BPLA2G5 | |
| SCHEMBL23991794 | 0.80 | ALDH1A1 (0.58) | CNR1CNR2ALDH1A1 | |
| SCHEMBL11961097 | 0.80 | ALDH1A1 (0.58) | CNR1CNR2ALDH1A1 | |
| SCHEMBL3488149 | 0.80 | ALDH1A1 (0.58) | CNR1CNR2ALDH1A1 | |
| SCHEMBL11913760 | 0.80 | ALDH1A1 (0.58) | CNR1CNR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3100718-A1 | IMPROVED COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | Arbutus Biopharma Corporation (CA) | 2016-12-07 | — | — | EP | disclosed |
| EP-3100718-A1 | IMPROVED COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | Arbutus Biopharma Corporation (CA) | 2016-12-07 | — | — | EP | disclosed |
| EP-2224912-B1 | IMPROVED COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORP (CA) | 2016-05-11 | — | — | EP | disclosed |
| US-20110117125-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2011-05-19 | — | — | US | disclosed |
| US-20110117125-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2011-05-19 | — | — | US | disclosed |
| US-20110117125-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2011-05-19 | — | — | US | disclosed |
| WO-2009086558-A1 | IMPROVED COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | TEKMIRA PHARMACEUTICALS CORPORATION (CA) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110117125-A1 | COMPOSITIONS AND METHODS FOR THE DELIVERY OF NUCLEIC ACIDS | LDLR, SNRPE, SARNP | CNR1 4139/4885CNR2 4446/4885ALDH1A1 4156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.